Product image of Ocrevus (Ocrelizumab) supplied by GNH India

Ocrevus

Active Ingredient:
Ocrelizumab
Origin:
EU

Ocrevus (Ocrelizumab)

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a 150 mg per vial solution for injection for subcutaneous use. It treats relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in adult patients.

GNH India supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Roche Registration Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ocrevus is indicated as a disease‑modifying therapy for multiple sclerosis, targeting B‑cell activity.

  • Relapsing‑Remitting Multiple Sclerosis: reduces frequency of clinical relapses and slows disability progression.
  • Primary Progressive Multiple Sclerosis: delays accumulation of disability in adults.
  • Active Disease Activity in Multiple Sclerosis: helps control MRI‑detected lesions and clinical activity.

How It Works

  • Ocrelizumab is a humanized monoclonal antibody that selectively binds to the CD20 surface antigen on pre‑B and mature B lymphocytes. This binding triggers antibody‑dependent cellular cytotoxicity and complement‑mediated lysis, leading to depletion of circulating CD20‑positive B cells. The reduction of B‑cell populations modulates the autoimmune response implicated in the pathogenesis of multiple sclerosis.

Side Effects

Ocrevus may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Infusion‑related reactions: flushing, rash, pruritus, or mild fever.
  • Upper respiratory tract infections: nasopharyngitis, sinusitis, or cough.
  • Headache: mild to moderate intensity.
  • Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects

  • Severe infections: opportunistic infections such as tuberculosis or viral hepatitis.
  • Hepatitis B reactivation: liver inflammation in previously infected individuals.
  • Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain infection.
  • Malignancies: increased incidence of certain cancers reported in clinical trials.

Precautions & Warnings

When prescribing Ocrevus, clinicians should consider several precautionary measures to ensure patient safety.

  • Screening: test for active hepatitis B infection before initiating therapy.
  • Vaccination: administer required vaccines, especially live vaccines, prior to treatment.
  • Monitoring: regularly assess complete blood counts and liver function tests during therapy.
  • Infection risk: advise patients to report signs of infection promptly and avoid exposure to contagious diseases.
  • Pregnancy: avoid use during pregnancy; discuss contraception and potential risks with women of childbearing potential.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Avoid Interactions

Ocrevus can interact with other medicines, influencing its safety or efficacy.

Major Interactions (Avoid)

  • Live vaccines: concurrent administration may lead to severe infection due to immunosuppression.
  • Antiviral therapy for hepatitis B: may be insufficient without prophylactic antiviral coverage.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive agents: combined use may increase infection risk.
  • CYP450 substrates: no direct metabolism, but monitor for additive immunosuppression.
  • Concomitant monoclonal antibodies: overlapping mechanisms may heighten adverse event profile.

Frequently Asked Questions

Ocrevus is prescribed for adults with relapsing forms of multiple sclerosis, including relapsing‑remitting disease, as well as for primary progressive multiple sclerosis. It acts as a disease‑modifying therapy aimed at reducing relapse frequency and slowing disability progression.

Ocrelizumab is a monoclonal antibody that binds selectively to the CD20 antigen on B lymphocytes. This binding triggers immune mechanisms that destroy CD20‑positive B cells, leading to their depletion and thereby reducing the autoimmune activity that contributes to multiple sclerosis pathology.

The specific dosing regimen for Ocrevus is determined by the prescribing clinician based on the patient’s condition, weight, and treatment plan. Dosage details are provided in the product’s prescribing information and should be followed exactly as directed by a qualified healthcare professional.

The safety of Ocrevus in pregnancy and lactation has not been established. It is generally advised to avoid use during pregnancy and to discuss alternative options with a healthcare provider. Women of childbearing potential should use effective contraception while receiving treatment.

To request Ocrevus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Ocrevus is a monoclonal antibody that depletes CD20‑positive B cells, whereas many other disease‑modifying therapies target different pathways, such as interferon signaling or sphingosine‑1‑phosphate receptors. Its unique mechanism offers an alternative for patients who may not respond adequately to other classes.

Ocrevus vials should be stored at 2 °C to 8 °C (refrigerated). Keep them in the original packaging, protect from light, and avoid freezing or shaking the solution. Proper cold‑chain handling is essential to maintain product stability.

Ocrevus is supplied as a solution for injection and is administered subcutaneously by a healthcare professional. The injection is performed in a clinical setting following aseptic technique, and patients are monitored for any immediate infusion‑related reactions.

Serious risks include severe infections such as opportunistic bacterial, viral, or fungal diseases, reactivation of hepatitis B, progressive multifocal leukoencephalopathy (PML), and an increased incidence of certain malignancies. Patients should be monitored closely for signs of infection or abnormal laboratory findings.

Ocrevus is contraindicated in individuals with active hepatitis B infection and should be used with caution in patients with a history of serious infections or malignancies. It is also not recommended for pregnant or breastfeeding women unless the potential benefits outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ocrelizumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT